129 related articles for article (PubMed ID: 10217343)
21. Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects.
Flesch G; Tudor D; Denouel J; Bonner J; Camisasca R
Int J Clin Pharmacol Ther; 2003 Jul; 41(7):299-308. PubMed ID: 12875346
[TBL] [Abstract][Full Text] [Related]
22. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.
Lu Y; Fang Y; Wu X; Ma C; Wang Y; Xu L
Eur J Clin Pharmacol; 2017 Mar; 73(3):307-315. PubMed ID: 27900402
[TBL] [Abstract][Full Text] [Related]
23. Plasma level monitoring of oxcarbazepine in epileptic patients.
González-Esquivel DF; Ortega-Gavilán M; Alcántara-López G; Jung-Cook H
Arch Med Res; 2000; 31(2):202-5. PubMed ID: 10880728
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
Peng J; Zhang HN; Liu ZS; Xu H; Wang Y
Int J Clin Pharmacol Ther; 2014 Aug; 52(8):684-92. PubMed ID: 24887335
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy.
Chen CY; Zhou Y; Cui YM; Yang T; Zhao X; Wu Y
J Clin Pharm Ther; 2019 Apr; 44(2):300-311. PubMed ID: 30636182
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous quantitative analysis of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine in human plasma by liquid chromatography-electrospray tandem mass spectrometry.
de Sousa Maia MB; do Nascimento DF; Martins IL; Cunha AN; de Lima FE; Bezerra FA; de Moraes MO; de Moraes ME
J Pharm Biomed Anal; 2007 Oct; 45(2):304-11. PubMed ID: 17869472
[TBL] [Abstract][Full Text] [Related]
27. Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms.
Yang X; Yan Y; Fang S; Zeng S; Ma H; Qian L; Chen X; Wei J; Gong Z; Xu Z
Medicine (Baltimore); 2019 Mar; 98(12):e14908. PubMed ID: 30896644
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens.
Lin WW; Li XW; Jiao Z; Zhang J; Rao X; Zeng DY; Lin XH; Wang CL
Eur J Clin Pharmacol; 2019 Mar; 75(3):381-392. PubMed ID: 30456415
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs.
Isoherranen N; Yagen B; Soback S; Roeder M; Schurig V; Bialer M
Epilepsia; 2001 Jul; 42(7):825-30. PubMed ID: 11488879
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.
Elger C; Bialer M; Falcão A; Vaz-da-Silva M; Nunes T; Almeida L; Soares-da-Silva P
Epilepsia; 2013 Aug; 54(8):1453-61. PubMed ID: 23758485
[TBL] [Abstract][Full Text] [Related]
31. Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD).
Miles MV; Tang PH; Ryan MA; Grim SA; Fakhoury TA; Strawsburg RH; DeGrauw TJ; Baumann RJ
Ther Drug Monit; 2004 Jun; 26(3):300-4. PubMed ID: 15167632
[TBL] [Abstract][Full Text] [Related]
32. Removal of 10-hydroxycarbazepine by plasmapheresis.
Christensen J; Balslev T; Villadsen J; Heinsvig EM; Dam M; Poulsen JH
Ther Drug Monit; 2001 Aug; 23(4):374-9. PubMed ID: 11477319
[TBL] [Abstract][Full Text] [Related]
33. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients.
McKee PJ; Blacklaw J; Forrest G; Gillham RA; Walker SM; Connelly D; Brodie MJ
Br J Clin Pharmacol; 1994 Jan; 37(1):27-32. PubMed ID: 8148215
[TBL] [Abstract][Full Text] [Related]
34. Quantification of oxcarbazeipine and its active metabolite 10-hydroxycarbazepine in human plasma by high-performance liquid chromatography.
Nirogi RV; Kandikere VN; Shukla M; Mudigonda K; Ajjala DR
Arzneimittelforschung; 2006; 56(7):517-23. PubMed ID: 16927533
[TBL] [Abstract][Full Text] [Related]
35. First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite.
Dickinson RG; Hooper WD; Dunstan PR; Eadie MJ
Eur J Clin Pharmacol; 1989; 37(1):69-74. PubMed ID: 2591466
[TBL] [Abstract][Full Text] [Related]
36. Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex.
Marino SE; Birnbaum AK; Leppik IE; Conway JM; Musib LC; Brundage RC; Ramsay RE; Pennell PB; White JR; Gross CR; Rarick JO; Mishra U; Cloyd JC
Clin Pharmacol Ther; 2012 Mar; 91(3):483-8. PubMed ID: 22278332
[TBL] [Abstract][Full Text] [Related]
37. Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy.
Wegner I; Edelbroek P; de Haan GJ; Lindhout D; Sander JW
Epilepsia; 2010 Dec; 51(12):2500-2. PubMed ID: 21204816
[TBL] [Abstract][Full Text] [Related]
38. Stereoselective pharmacokinetics and metabolism of the enantiomers of cyclophosphamide. Preliminary results in humans and rabbits.
Holm KA; Kindberg CG; Stobaugh JF; Slavik M; Riley CM
Biochem Pharmacol; 1990 Apr; 39(8):1375-84. PubMed ID: 2322319
[TBL] [Abstract][Full Text] [Related]
39. Stereoselective disposition of S- and R-licarbazepine in mice.
Alves G; Figueiredo I; Falcão A; Castel-Branco M; Caramona M; Soares-Da-Silva P
Chirality; 2008 Jun; 20(6):796-804. PubMed ID: 18306292
[TBL] [Abstract][Full Text] [Related]
40. Oxcarbazepine final market image tablet formulation bioequivalence study after single administration and at steady state in healthy subjects.
Flesch G; Tudor D; Souppart C; D'Souza J; Hossain M
Int J Clin Pharmacol Ther; 2002 Nov; 40(11):524-32. PubMed ID: 12698990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
